8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 6, 2007

IRIDEX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-27598	77-0210467
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation)		Identification No.)

1212 Terra Bella Avenue
Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

EXHIBIT 99.1

Item 1.01. Entry Into a Material Definitive Agreement.

     On January 9, 2007, Meryl A. Rains accepted an offer of employment from IRIDEX Corporation (“IRIDEX” or the “Company”) for the position of Chief Financial Officer. The material terms of Ms. Rains employment offer are set forth below in Item 5.02(c) and incorporated herein by reference.

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

     (b) On February 5, 2007, Larry Tannenbaum resigned as Chief Financial Officer and transitioned into the role of Chief Business Officer concurrently with the commencement of Meryl A. Rains’ employment with IRIDEX as the Company’s new Vice President and Chief Financial Officer.

     (c) On February 5, 2007, Meryl A. Rains, age 44, commenced employment as the Company’s new Vice President and Chief Financial Officer.

     From August 2004 to February 2007, Ms. Rains served as Corporate Controller of Actel Corporation, a fabless semiconductor company. From February 2004 to August 2004, Ms. Rains served as Interim Controller of Asyst Technologies, Inc., a semiconductor equipment manufacturer. From November 2002 to February 2004, Ms. Rains served as a consultant to various private and public companies. From January 2000 to November 2002, Ms. Rains was Controller at Celestica, Inc., a global contract manufacturer. Ms. Rains served as Corporate Controller of International Manufacturing Services (acquired by Celestica, Inc.) from 1996-1999.

     There are no family relationships between Ms. Rains and any executive officers, directors, or other employees of the Company. Ms. Rains has no material interests in any transactions or proposed transactions with the Company.

     Pursuant to an employment offer letter entered into by and between the Company and Ms. Rains on January 9, 2007 (the “Offer Letter”), Ms. Rains will receive an annualized base salary of $215,000, and will be eligible to participate in the Company’s existing profit and executive bonus programs. Ms. Rains will also receive a “sign-on” bonus of $35,000, subject to repayment on a pro-rated basis in the event that Ms. Rains voluntarily terminates her employment with the Company during the twelve-month period following the commencement of her employment.

     In addition, the Offer Letter provides that the Company’s Board of Directors will grant Ms. Rains a non-qualified stock option outside of the Company’s existing stock plans and as a material inducement to Ms. Rains accepting employment with the Company (the “Stand-Alone Option”), which entitles Ms. Rains to purchase up to 50,000 shares of the Company’s common stock, at an exercise price equal to the fair market value of the Company’s common stock on the date such option is granted. The shares underlying the Stand-Alone Option will vest over a four (4) year period, with 1/4^th of the total number of shares subject to the Stand-Alone Option vesting on the first anniversary of the date on which Ms. Rains commenced her employment with the Company and 1/48^th of the total number of shares subject to the Stand-Alone Option vesting each full month thereafter, provided that Ms. Rains continues to be a service provider to the Company on each such date.

Item 9.01. Financial Statements and Exhibits.

(d)      Exhibits.

Exhibit
Number	Description
99.1	Press Release dated February 6, 2007.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IRIDEX CORPORATION
	By:	/s/ Barry G. Caldwell
Date: February 9, 2007		Barry G. Caldwell President and Chief Executive Officer

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release dated February 6, 2007.

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE	Contact:	Larry Tannenbaum
		Chief Business Officer
		(650) 940-4700

February 6, 2007
Mountain View, California

IRIDEX NAMES MERYL RAINS CHIEF FINANCIAL OFFICER

Larry Tannenbaum Named to New Position of Chief Business Officer
To Focus on Integrating Recently Acquired Laserscope Aesthetics Business
and New Business Development

IRIDEX Corporation (NASDAQ: IRIX) today announced that Meryl A. Rains, 44, has joined the Company as Chief Financial Officer. Ms. Rains replaces Larry Tannenbaum, 55, who has been named the Company’s first Chief Business Officer responsible for overseeing IRIDEX’s corporate business development and the integration of the Laserscope aesthetics business which was acquired on January 16, 2007. Mr. Tannenbaum will continue to assist with investor relations activities and will coordinate the transition of CFO duties to Ms. Rains. Mr. Tannenbaum served as the Chief Financial Officer of IRIDEX since April 2004.

“With the expansion of our operations to include the aesthetics business of Laserscope, we recognized a need to deepen our management team and are fortunate to have Larry’s business expertise and acumen already on board,” said Barry Caldwell, President and Chief Executive Officer. “In the newly created role of Chief Business Officer, we believe that Larry’s proven leadership capabilities, knowledge of our industry and insights into our company will allow him to have an even greater impact on our business.

“We are also very excited to welcome Meryl to IRIDEX and believe that her strong financial management and control experience will result in an immediate contribution to our team,” continued Mr. Caldwell. “Meryl has over 17 years of senior financial management experience as a certified public accountant and has extensive experience in managing the financial operations and compliance requirements of publicly traded companies. In addition, her strong background in tax and law should allow us to proactively develop our tax and legal strategies especially with regard to our recently acquired international subsidiaries.”

“In our search to fill the role of Chief Financial Officer, we were looking for an individual with extensive experience in every aspect of financial reporting, planning and control,” said Mr. Tannenbaum. “We believe Meryl’s skill-set, which includes SEC financial reporting, Sarbanes-Oxley compliance, financial planning and analysis and international finance make her specifically qualified to succeed in this role. We look forward to her contributions and I look forward to working with her during the transition of the CFO responsibilities.”

Prior to joining IRIDEX, Ms. Rains was the Corporate Controller of Actel Corporation, a $200 million publicly traded semiconductor company with global operations. In this role she was responsible for worldwide accounting and financial reporting, financial planning and analysis, tax, treasury and Sarbanes-Oxley compliance. Previously, Ms. Rains had served in controllership roles for Celestica, Inc. and International Manufacturing Services, both publicly traded, global contract manufacturers. Prior to that, Ms. Rains held financial management positions as Treasurer and Sr. Director of Tax at Maxtor Corporation and served as International Tax Managers at each of Borland International, Inc. and Price Waterhouse.

Ms. Rains holds a Doctor of Jurisprudence from the University of Denver College of Law and a Bachelor of Science from the Metropolitan State College of Denver. She is also a member of the California Bar Association and a Certified Public Accountant.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 97 independent distributors into 107 countries. For further information, visit the Company’s website at www.iridex.com

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company’s prior Chief Financial Officer’s continued involvement and assistance with the transition to the Company’s new Chief Financial Officer, Mr. Tannenbaum’s future impact as the Company’s Chief Business Officer, the timing and impact of Ms. Rains’ contributions to the Company, and the development of the Company’s tax and legal strategies. Actual results could differ materially and adversely from those projected in the forward- looking statements based on, among other things, the actual order and shipment rate for the Company’s ophthalmology and dermatology product lines, the rate of sales to OEM customers, the rate of growth in sales of disposables and services, our ability to reduce expenses, the closing of pending acquisitions, our ability to remediate material weaknesses in our disclosure controls and the impact of any continuing weakness and uncertainties related to general economic conditions or weakness in overall demand in the Company’s markets, especially with regard to the Company’s dermatology products which are typically used for elective procedures that can be deferred. Additional risks and uncertainties to which the Company are subject may include, but may not necessarily be limited to, the amount of orders that the Company receives and ships, dependence on international sales and the Company’s network of independent distributors, the risks associated with bringing new products to market, and the results of clinical trials and competition in our markets, as well as the risks associated with a competitive market for management talent and the risks inherent with identifying, negotiating and integrating strategic acquisitions of complementary businesses, products or technologies. Please see a detailed

description of these risks contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 31, 2005 filed with the Securities and Exchange Commission. Forward- looking statements contained in this announcement are made as of this date and will not be updated.